Immunogenicity Risk Profile of Nanobodies

Abstract

Nanobodies, the recombinant single domain affinity reagents derived from heavy chain-only antibodies in camelids, are proven to possess a low immunogenicity risk profile, which will facilitate a growing number of Nanobodies to enter the clinic for therapeutic or <i>in vivo</i> diagnostic applications.